Dear All,Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two funding calls during 2026 (April and then Q4) and (ii) that a theme focused on finding new chemical scaffolds will be part of both calls. Applications to these target-based therapeutics funding calls will require defined chemistry plans based on literature evidence suggesting that novel chemistry scaffolds with activity against validated bacterial targets can be found.Plans must be focused on one of the following five structurally enabled molecular targets:These three clinically validated broad-spectrum targets:Ribosome: responsible for protein synthesis, the ribosome is the clinically validated target of many classes of antibacterial agents (aminoglycosides, macrolides, tetracyclines, etc.)Penicillin-binding proteins: responsible for synthesis of cell wall peptidoglycan, the PBPs are the clinically validated targets of both β-lactam and some classes of non-β-lactam antibioticsType II Topoisomerases: responsible for maintaining DNA topology in an ATP-dependent manner during DNA replication, these proteins are the clinically validated targets of the quinolone and new NBTI classes of antibioticsThese two pre-clinically validated Gram-negative targets:LpxH: an essential enzyme in the lipid A biosynthetic pathway of Gram-negative bacteriaLolCDE: an essential ATP-binding cassette (ABC) transporter system involved in lipoprotein transport in Gram-negative bacteria Organic chemists with an interest in...